Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00805467 · ClinicalTrials.gov registry record · Phase 2
Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 624
- Enrollment target
NCT00805467: Clinical Trial Phase 2 study, sponsored by AstraZeneca.
NCT00805467 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 624 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (369% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00805467, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 624 participants
- Enrollment target
Study Summary
The purpose of this new research study is to gain additional information about how safe and effective R935788 is over a longer period of time.
Primary Outcome
AE = adverse event, bid = twice daily, IP = investigational product, qd = once daily, SAE = serious adverse event
Interventions
- DRUG Fostamatinib Disodium (R935788)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 624 participants |
| Start Date | 2008-08 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Why NCT00805467 stopped before completion
NCT00805467 is an interventional study that assigns participants to a tested intervention. The registered 624 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (369% higher).
The record links to 0 conditions, and to 1 intervention - of which Fostamatinib Disodium (R935788) is the first listed.
NCT00805467 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00805467 about?
NCT00805467 is a clinical study titled "Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies". The purpose of this new research study is to gain additional information about how safe and effective R935788 is over a longer period of time.
What is the current status of trial NCT00805467?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 624 participants. The study started on 2008-08. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00805467?
The interventions under investigation include: Fostamatinib Disodium (R935788) (DRUG).
Who is sponsoring clinical trial NCT00805467?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00805467's enrollment target sits among peer trials
624 52nd of 2000 higher than 1,949 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06406049 · 624 participants · NA
Finishing HIV Project
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia